Send to

Choose Destination
Ther Adv Hematol. 2012 Dec;3(6):333-9. doi: 10.1177/2040620712458948.

Next-generation sequencing in hematologic malignancies: what will be the dividends?

Author information

Department of Pathology, Stanford University School of Medicine, Stanford, CA 94304, USA.


The application of high-throughput, massively parallel sequencing technologies to hematologic malignancies over the past several years has provided novel insights into disease initiation, progression, and response to therapy. Here, we describe how these new DNA sequencing technologies have been applied to hematolymphoid malignancies. With further improvements in the sequencing and analysis methods as well as integration of the resulting data with clinical information, we expect these technologies will facilitate more precise and tailored treatment for patients with hematologic neoplasms.


exome sequencing; genome sequencing; hematologic; high-throughput sequencing; massively parallel sequencing; next-generation sequencing; sequencing technologies

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center